Demonstrating efficacy in preclinical studies of cellular therapies for spinal cord injury - How much is enough?

Brian K. Kwon, Lesley J J Soril, Mark Bacon, Michael S. Beattie, Armin Blesch, Jacqueline C. Bresnahan, Mary Bartlett Bunge, Sarah A. Dunlop, Michael G. Fehlings, Adam R. Ferguson, Caitlin E. Hill, Soheila Karimi-Abdolrezaee, Paul Lu, John W. McDonald, Hans W. Müller, Martin Oudega, Ephron S. Rosenzweig, Paul J. Reier, Jerry Silver, Eva SykovaXiao-Ming Xu, James D. Guest, Wolfram Tetzlaff

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Cellular therapies represent a novel treatment approach for spinal cord injury (SCI), with many different cellular substrates showing promise in preclinical animal models of SCI. Considerable interest therefore exists to translate such cellular interventions into human clinical trials. Balanced against the urgency for clinical translation is the desire to establish the robustness of a cellular therapy's efficacy in preclinical studies, thereby optimizing its chances of succeeding in human trials. Uncertainty exists, however, on the extent to which a therapy needs to demonstrate efficacy in the preclinical setting in order to justify the initiation of a lengthy, expensive, and potentially risky clinical trial. The purpose of this initiative was to seek perspectives on the level of evidence required in experimental studies of cellular therapies before proceeding with clinical trials of SCI. We conducted a survey of 27 SCI researchers actively involved in either preclinical and/or clinical research of cellular interventions for SCI, and then held a focus group meeting to facilitate more in-depth discussion around a number of translational issues. These included: the use of animal models, the use of injury models and mechanisms, the window for demonstrating efficacy, independent replication, defining "relevant, meaningful efficacy" in preclinical studies, and the expectation of therapeutic benefits for cellular interventions. Here we present the key findings from both the survey and focus group meeting in order to summarize and underscore the areas of consensus and disagreement amongst the sampled researchers. It is anticipated that the knowledge generated from this initiative will help to incite future scientific discussions and expert guidelines towards translation of a cell therapy for persons with SCI.

Original languageEnglish
Pages (from-to)30-44
Number of pages15
JournalExperimental Neurology
Volume248
DOIs
StatePublished - Oct 2013

Fingerprint

Spinal Cord Injuries
Group Processes
Clinical Trials
Focus Groups
Therapeutics
Animal Models
Research Personnel
Cell- and Tissue-Based Therapy
Uncertainty
Consensus
Guidelines
Wounds and Injuries
Research

Keywords

  • Animal model
  • Cell transplantation therapies
  • Clinical trial
  • Preclinical studies
  • Spinal cord injury
  • Stem cell

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Kwon, B. K., Soril, L. J. J., Bacon, M., Beattie, M. S., Blesch, A., Bresnahan, J. C., ... Tetzlaff, W. (2013). Demonstrating efficacy in preclinical studies of cellular therapies for spinal cord injury - How much is enough? Experimental Neurology, 248, 30-44. https://doi.org/10.1016/j.expneurol.2013.05.012

Demonstrating efficacy in preclinical studies of cellular therapies for spinal cord injury - How much is enough? / Kwon, Brian K.; Soril, Lesley J J; Bacon, Mark; Beattie, Michael S.; Blesch, Armin; Bresnahan, Jacqueline C.; Bunge, Mary Bartlett; Dunlop, Sarah A.; Fehlings, Michael G.; Ferguson, Adam R.; Hill, Caitlin E.; Karimi-Abdolrezaee, Soheila; Lu, Paul; McDonald, John W.; Müller, Hans W.; Oudega, Martin; Rosenzweig, Ephron S.; Reier, Paul J.; Silver, Jerry; Sykova, Eva; Xu, Xiao-Ming; Guest, James D.; Tetzlaff, Wolfram.

In: Experimental Neurology, Vol. 248, 10.2013, p. 30-44.

Research output: Contribution to journalArticle

Kwon, BK, Soril, LJJ, Bacon, M, Beattie, MS, Blesch, A, Bresnahan, JC, Bunge, MB, Dunlop, SA, Fehlings, MG, Ferguson, AR, Hill, CE, Karimi-Abdolrezaee, S, Lu, P, McDonald, JW, Müller, HW, Oudega, M, Rosenzweig, ES, Reier, PJ, Silver, J, Sykova, E, Xu, X-M, Guest, JD & Tetzlaff, W 2013, 'Demonstrating efficacy in preclinical studies of cellular therapies for spinal cord injury - How much is enough?', Experimental Neurology, vol. 248, pp. 30-44. https://doi.org/10.1016/j.expneurol.2013.05.012
Kwon, Brian K. ; Soril, Lesley J J ; Bacon, Mark ; Beattie, Michael S. ; Blesch, Armin ; Bresnahan, Jacqueline C. ; Bunge, Mary Bartlett ; Dunlop, Sarah A. ; Fehlings, Michael G. ; Ferguson, Adam R. ; Hill, Caitlin E. ; Karimi-Abdolrezaee, Soheila ; Lu, Paul ; McDonald, John W. ; Müller, Hans W. ; Oudega, Martin ; Rosenzweig, Ephron S. ; Reier, Paul J. ; Silver, Jerry ; Sykova, Eva ; Xu, Xiao-Ming ; Guest, James D. ; Tetzlaff, Wolfram. / Demonstrating efficacy in preclinical studies of cellular therapies for spinal cord injury - How much is enough?. In: Experimental Neurology. 2013 ; Vol. 248. pp. 30-44.
@article{9831e244a21c495794438f382815028a,
title = "Demonstrating efficacy in preclinical studies of cellular therapies for spinal cord injury - How much is enough?",
abstract = "Cellular therapies represent a novel treatment approach for spinal cord injury (SCI), with many different cellular substrates showing promise in preclinical animal models of SCI. Considerable interest therefore exists to translate such cellular interventions into human clinical trials. Balanced against the urgency for clinical translation is the desire to establish the robustness of a cellular therapy's efficacy in preclinical studies, thereby optimizing its chances of succeeding in human trials. Uncertainty exists, however, on the extent to which a therapy needs to demonstrate efficacy in the preclinical setting in order to justify the initiation of a lengthy, expensive, and potentially risky clinical trial. The purpose of this initiative was to seek perspectives on the level of evidence required in experimental studies of cellular therapies before proceeding with clinical trials of SCI. We conducted a survey of 27 SCI researchers actively involved in either preclinical and/or clinical research of cellular interventions for SCI, and then held a focus group meeting to facilitate more in-depth discussion around a number of translational issues. These included: the use of animal models, the use of injury models and mechanisms, the window for demonstrating efficacy, independent replication, defining {"}relevant, meaningful efficacy{"} in preclinical studies, and the expectation of therapeutic benefits for cellular interventions. Here we present the key findings from both the survey and focus group meeting in order to summarize and underscore the areas of consensus and disagreement amongst the sampled researchers. It is anticipated that the knowledge generated from this initiative will help to incite future scientific discussions and expert guidelines towards translation of a cell therapy for persons with SCI.",
keywords = "Animal model, Cell transplantation therapies, Clinical trial, Preclinical studies, Spinal cord injury, Stem cell",
author = "Kwon, {Brian K.} and Soril, {Lesley J J} and Mark Bacon and Beattie, {Michael S.} and Armin Blesch and Bresnahan, {Jacqueline C.} and Bunge, {Mary Bartlett} and Dunlop, {Sarah A.} and Fehlings, {Michael G.} and Ferguson, {Adam R.} and Hill, {Caitlin E.} and Soheila Karimi-Abdolrezaee and Paul Lu and McDonald, {John W.} and M{\"u}ller, {Hans W.} and Martin Oudega and Rosenzweig, {Ephron S.} and Reier, {Paul J.} and Jerry Silver and Eva Sykova and Xiao-Ming Xu and Guest, {James D.} and Wolfram Tetzlaff",
year = "2013",
month = "10",
doi = "10.1016/j.expneurol.2013.05.012",
language = "English",
volume = "248",
pages = "30--44",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Demonstrating efficacy in preclinical studies of cellular therapies for spinal cord injury - How much is enough?

AU - Kwon, Brian K.

AU - Soril, Lesley J J

AU - Bacon, Mark

AU - Beattie, Michael S.

AU - Blesch, Armin

AU - Bresnahan, Jacqueline C.

AU - Bunge, Mary Bartlett

AU - Dunlop, Sarah A.

AU - Fehlings, Michael G.

AU - Ferguson, Adam R.

AU - Hill, Caitlin E.

AU - Karimi-Abdolrezaee, Soheila

AU - Lu, Paul

AU - McDonald, John W.

AU - Müller, Hans W.

AU - Oudega, Martin

AU - Rosenzweig, Ephron S.

AU - Reier, Paul J.

AU - Silver, Jerry

AU - Sykova, Eva

AU - Xu, Xiao-Ming

AU - Guest, James D.

AU - Tetzlaff, Wolfram

PY - 2013/10

Y1 - 2013/10

N2 - Cellular therapies represent a novel treatment approach for spinal cord injury (SCI), with many different cellular substrates showing promise in preclinical animal models of SCI. Considerable interest therefore exists to translate such cellular interventions into human clinical trials. Balanced against the urgency for clinical translation is the desire to establish the robustness of a cellular therapy's efficacy in preclinical studies, thereby optimizing its chances of succeeding in human trials. Uncertainty exists, however, on the extent to which a therapy needs to demonstrate efficacy in the preclinical setting in order to justify the initiation of a lengthy, expensive, and potentially risky clinical trial. The purpose of this initiative was to seek perspectives on the level of evidence required in experimental studies of cellular therapies before proceeding with clinical trials of SCI. We conducted a survey of 27 SCI researchers actively involved in either preclinical and/or clinical research of cellular interventions for SCI, and then held a focus group meeting to facilitate more in-depth discussion around a number of translational issues. These included: the use of animal models, the use of injury models and mechanisms, the window for demonstrating efficacy, independent replication, defining "relevant, meaningful efficacy" in preclinical studies, and the expectation of therapeutic benefits for cellular interventions. Here we present the key findings from both the survey and focus group meeting in order to summarize and underscore the areas of consensus and disagreement amongst the sampled researchers. It is anticipated that the knowledge generated from this initiative will help to incite future scientific discussions and expert guidelines towards translation of a cell therapy for persons with SCI.

AB - Cellular therapies represent a novel treatment approach for spinal cord injury (SCI), with many different cellular substrates showing promise in preclinical animal models of SCI. Considerable interest therefore exists to translate such cellular interventions into human clinical trials. Balanced against the urgency for clinical translation is the desire to establish the robustness of a cellular therapy's efficacy in preclinical studies, thereby optimizing its chances of succeeding in human trials. Uncertainty exists, however, on the extent to which a therapy needs to demonstrate efficacy in the preclinical setting in order to justify the initiation of a lengthy, expensive, and potentially risky clinical trial. The purpose of this initiative was to seek perspectives on the level of evidence required in experimental studies of cellular therapies before proceeding with clinical trials of SCI. We conducted a survey of 27 SCI researchers actively involved in either preclinical and/or clinical research of cellular interventions for SCI, and then held a focus group meeting to facilitate more in-depth discussion around a number of translational issues. These included: the use of animal models, the use of injury models and mechanisms, the window for demonstrating efficacy, independent replication, defining "relevant, meaningful efficacy" in preclinical studies, and the expectation of therapeutic benefits for cellular interventions. Here we present the key findings from both the survey and focus group meeting in order to summarize and underscore the areas of consensus and disagreement amongst the sampled researchers. It is anticipated that the knowledge generated from this initiative will help to incite future scientific discussions and expert guidelines towards translation of a cell therapy for persons with SCI.

KW - Animal model

KW - Cell transplantation therapies

KW - Clinical trial

KW - Preclinical studies

KW - Spinal cord injury

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=84879361259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879361259&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2013.05.012

DO - 10.1016/j.expneurol.2013.05.012

M3 - Article

C2 - 23727091

AN - SCOPUS:84879361259

VL - 248

SP - 30

EP - 44

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

ER -